|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar
|
|
2
|
American Cancer Society: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html retrieved on 23.12.09.
|
|
3
|
Lee MI, Jung YJ, Kim DI, Paik HJ, Lee S, Jung CS, Kim JY and Kim HY: Metastasis to breast from ovarian cancer and primary ovarian cancer concurrently diagnosis. Gland Surg. 10:1806–1811. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, et al: Neoplastic stem cells: Current concepts and clinical perspectives. Crit Rev Oncol Hematol. 76:79–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, et al: Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 8:e818592013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST and Mok SC: Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 309:C444–C4456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G, Polacheck WJ, Roque DM, et al: Malignant ascites in ovarian cancer: Cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel). 13:43182021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grunt TW: Interacting Cancer Machineries: Cell signaling, lipid metabolism, and epigenetics. Trends Endocrinol Metab. 29:86–98. 2018. View Article : Google Scholar
|
|
10
|
Scaglia N, Frontini-López YR and Zadra G: Prostate cancer progression: As a matter of fats. Front Oncol. 11:7198652021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao Y, Yi Q, XiaoWu X, WeiBo C, GuangChen Z and XueMin C: Acetyl-CoA: An interplay between metabolism and epigenetics in cancer. Front Mol Med. 2:10445852022. View Article : Google Scholar
|
|
12
|
Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Ogishima J, et al: Detachment from the primary site and suspension in ascites as the initial step in metabolic reprogramming and metastasis to the omentum in ovarian cancer. Oncol Lett. 15:1357–1361. 2018.PubMed/NCBI
|
|
13
|
Chen RR, Yung MMH, Xuan Y, Zhan S, Leung LL, Liang RR, Leung THY, Yang H, Xu D, Sharma R, et al: Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol. 2:2812019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grunt TW, Slany A, SemkovaM, Colomer R, López-Rodrı́guez ML, Wuczkowski M, Wagner R, Gerner C and Stübiger G: Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: A multi-omics analysis in ovarian cancer. Sci Rep. 10:148772020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lemberger L, Wagner R, Heller G, Pils D and Grunt TW: Pharmacological inhibition of lipid import and transport proteins in ovarian Cancer. Cancers (Basel). 14:60042022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng J, Zhang X and Yang G: Deregulation of lipid metabolism: The critical factors in ovarian cancer. Front Oncol. 10:5930172020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A and Testa JR: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 24:3574–3582. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, et al: Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget. 8:11600–11613. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomek K, Wagner R, Varga F, Singer CF, Karlic H and Grunt TW: Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res. 9:1767–1779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, et al: Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int J Cancer. 136:2078–2090. 2015. View Article : Google Scholar
|
|
21
|
Grunt TW, Lemberger L, Colomer R, López Rodríguez ML and Wagner R: The pharmacological or genetic blockade of endogenous de novo fatty acid synthesis does not increase the uptake of exogenous lipids in ovarian cancer cells. Front Oncol. 11:6108852021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC and Lupu R: Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 385:454–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang CS, Matsuura K, Huang NJ, Robeson AC, Huang B, Zhang L and Kornbluth S: Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. Oncogene. 34:3264–3272. 2015. View Article : Google Scholar :
|
|
24
|
Zhao G, Cardenas H and Matei D: Ovarian Cancer-Why Lipids Matter. Cancers (Basel). 26:18702019. View Article : Google Scholar
|
|
25
|
Gálvez BG, San Martín N and Rodríguez C: TNF-alpha is required for the attraction of mesenchymal precursors to white adipose tissue in Ob/ob mice. PLoS One. 4:e44442009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Drury J, Rychahou PG, He D, Jafari N, Wang C, Lee EY, Weiss HL, Evers BM and Zaytseva YY: Inhibition of fatty acid synthase upregulates expression of CD36 to sustain proliferation of colorectal cancer cells. Front Oncol. 10:11852020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai JM, Sun K, Li C, Cheng M, Guan JH, Yang LN and Zhang LW: Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α. Clin Transl Oncol. 25:1606–1616. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, et al: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 216:688–703. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, et al: Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 5:12017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grunt TW, Somay C, Oeller H, Dittrich E and Dittrich C: Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci. 103:501–509. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C and Grunt TW: Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer. 68:530–536. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á and Janovjak H: Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. EMBO J. 33:1713–1726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, Schelch K, Sinn K, Mosleh B, Hoda MA, et al: Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. J Exp Clin Cancer Res. 42:272023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Markowitz D, Goff S and Bank A: A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol. 62:1120–1124. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG and Kassem M: Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 20:592–596. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, et al: Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS One. 10:e01312412015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, et al: Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res. 15:7608–1765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Turrado C, Puig T, García-Cárceles J, Artola M, Benhamú B, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, et al: New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem. 55:5013–5023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, et al: Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 23:678–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hanahan D: Hallmarks of cancer: New dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, et al: Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian High-Grade serous carcinomas. Cancer Res. 76:796–804. 2016. View Article : Google Scholar :
|
|
43
|
Pua TL, Wang FQ and Fishman DA: Roles of LPA in ovarian cancer development and progression. Future Oncol. 5:1659–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, et al: The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol. 227:136–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim S, Kim B and Song YS: Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 107:1173–1178. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ghoneum A, Afify H, Salih Z, Kelly M and Said N: Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget. 9:22832–22849. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Impheng H, Pongcharoen S, Richert L, Pekthong D and Srisawang P: The selective target of capsaicin on FASN expression and de novo fatty acid synthesis mediated through ROS generation triggers apoptosis in HepG2 cells. PLoS One. 9:e1078422014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lou E, Vogel RI, Hoostal S, Klein M, Linden MA, Teoh D and Geller MA: Tumor-Stroma proportion as a predictive biomarker of resistance to Platinum-Based chemotherapy in patients with ovarian cancer. JAMA Oncol. 5:1222–1224. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Romanauska A and Köhler A: Reprogrammed lipid metabolism protects inner nuclear membrane against unsaturated fat. Dev Cell. 56:2562–2578. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniels VW, Machiels J, et al: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70:8117–8126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nieman KM, Romero IL, Van Houten B and Lengyel E: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, et al: Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 37:2285–2301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O and Lengyel E: Adipocyte-Induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res. 80:1748–1761. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, et al: Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 130:387–398. 2011. View Article : Google Scholar
|
|
55
|
Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D and Cheng JX: Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 20:303–314.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Grunt TW and Valent P: Increased lipid desaturation and ovarian cancer stem cells. Transl Cancer Res. 6(Suppl 3): S472–S475. 2017. View Article : Google Scholar
|
|
57
|
Cao Y: Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 129:3006–3017. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, et al: Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 9:24787–24800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wong A, Chen S, Yang LK, Kanagasundaram Y and Crasta K: Lipid accumulation facilitates mitotic slippage-induced adaptation to anti-mitotic drug treatment. Cell Death Discov. 4:1092018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Park R, Jang M, Park YI, Park Y, Namkoong S, Lee JI and Park J: Elevated levels of CTRP1 in obesity contribute to tumor progression in a p53-Dependent manner. Cancers (Basel). 13:36192021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Garcia DI, Hurst KE, Bradshaw A, Janakiraman H, Wang C and Camp ER: High-fat diet drives an aggressive pancreatic cancer phenotype. J Surg Res. 264:163–172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lombardi S, Goldman AR, Tang HY, Kossenkov AV, Liu H, Zhou W, Herlyn M, Lin J and Zhang R: Targeting fatty acid reprogramming suppresses CARM1-expressing ovarian cancer. Cancer Res Commun. 3:1067–1077. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bao J, Zhu L, Zhu Q, Su J, Liu M and Huang W: SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer. Oncol Lett. 12:2409–2416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nie LY, Lu QT, Li WH, Yang N, Dongol S, Zhang X and Jiang J: Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep. 30:1346–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
